Core Viewpoint - Beijing Sunshine Nuohua Pharmaceutical Research Co., Ltd. plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, while also raising matching funds from no more than 35 specific investors [1] Summary by Relevant Sections - **Transaction Details** - The company intends to purchase 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through a combination of share issuance and convertible bonds [1] - The company will also issue shares to raise matching funds from up to 35 specific investors [1] - **Stock Performance** - In the 20 trading days prior to the announcement of this transaction, the company's stock price increased by 9.82% [1] - Excluding the impact of market and industry factors, the stock price fluctuation did not exceed 20% during the same period, which is below the threshold set by the Shanghai Stock Exchange for significant asset restructuring [1] - There were no abnormal fluctuations in the company's stock trading prior to the announcement of the transaction [1]

Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management and entrust part of its idle self-owned funds for wealth management, aiming to enhance fund utilization efficiency and increase returns without affecting the implementation of fundraising projects and the normal operation of the company [1][4][6]. Investment Overview - **Investment Purpose**: The company aims to improve fund utilization efficiency and increase returns while ensuring the safety of raised funds and normal operations [1]. - **Investment Amount and Duration**: The company plans to use up to RMB 100 million of temporarily idle raised funds for cash management and up to RMB 300 million of idle self-owned funds for wealth management, with a validity period of 12 months from the board's approval [2][7]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a net amount of RMB 467.1815 million after deducting issuance costs [2][3]. Investment Products - The company will invest in safe, liquid, and legally compliant financial products, including but not limited to structured deposits, time deposits, large certificates of deposit, and wealth management products [3][4][7]. Implementation and Disclosure - The board of directors authorizes the general manager to make investment decisions within the specified limits, and the finance department is responsible for implementation [4][6]. - The company will fulfill its information disclosure obligations in accordance with relevant regulations and will not change the purpose of the raised funds [4][6]. Impact on Daily Operations - The use of idle raised funds for cash management and self-owned funds for wealth management will not affect the normal development of the company's main business and will help improve fund utilization efficiency and increase returns for the company and its shareholders [4][5]. Approval Procedures - The company held several meetings to approve the proposal for using idle funds, including the board of directors, audit and risk committee, and independent directors, all of whom expressed agreement with the plan [6][8]. Sponsor's Verification Opinion - The sponsor believes that the company's plan to use idle funds for cash management and wealth management has been properly approved and will enhance fund utilization efficiency without changing the purpose of the raised funds [9].

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年限制性股票激 励计划调整授予价格事项的 法律意见 京天股字（2025）第 153-3 号 致：北京阳光诺和药物研究股份有限公司 北京市天元律师事务所（以下简称本所）接受北京阳光诺和药物研究股份有 限公司（以下简称公司或阳光诺和）的委托，担任公司 2025 年限制性股票激励 计划（以下简称本激励计划）的专项中国法律顾问并出具法律意见。 本所及经办律师依据《中华人民共和国公司法》 （以下简称《公司法》）、 《中 华人民共和国证券法》 （以下简称《证券法》）、 《律师事务所从事证券法律业务管 理办法》《上市公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交 易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励 信息披露》等法律、法规和中国证券监督管理委员会（以下简称中国证监会）的 有关规定及本法律意见出具日以前已经发生或者存在的事实，按照 ...

Core Viewpoint - The legal opinion from Beijing Tianyuan Law Firm confirms that Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has complied with all necessary legal procedures for the initial grant of the 2025 restricted stock incentive plan [1][7]. Group 1: Legal Procedures - The initial grant of the incentive plan was approved by the company's board on May 12, 2025, and the relevant proposals were passed [3]. - The proposed incentive objects were publicly announced from May 13 to May 22, 2025, with no objections raised by employees [4]. - The second extraordinary general meeting of shareholders approved the incentive plan on May 28, 2025, and authorized the board to handle all necessary matters related to the grant [5]. Group 2: Grant Date and Conditions - The board determined the grant date for the incentive plan as June 11, 2025, which complies with relevant regulations [5][6]. - The conditions for granting the restricted stock include the absence of disqualifying circumstances as outlined in the management regulations [6]. - The company has verified that the initial grant of restricted stock to eligible incentive objects meets all legal and regulatory requirements [7].

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 差异化分红事项之 专项法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 差异化分红事项之专项法律意见 本所及经办律师依据《中华人民共和国公司法》 （以下简称《公司法》）、 《中 华人民共和国证券法》 （以下简称《证券法》）、 《律师事务所从事证券法律业务管 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 理办法》 （以下简 称《回购股份指引》）等法律、法规、 京天股字（2025）第 328 号 致：北京阳光诺和药物研究股份有限公司 北京市天元律师事务所（以下简称本所）接受北京阳光诺和药物研究股份有 限公司（以下简称公司或阳光诺和）的委托，就公司 2024 年度利润分配方案所 涉及的差异化事项（以下简称本次差异化分红）出具本法律意见。 《北京阳光诺和药物研究股份有限公司章程》 （以下简称《公司章程》）及本法律意见出具日以前已经发生或者存在的事实， 按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，出具本法律意 ...

北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称"公司"）第二届董事会独 立董事专门会议第六次会议于 2025 年 5 月 12 日在北京以现场与通讯相结合的方 式召开。会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议的召开符 合《中华人民共和国公司法》《上市公司独立董事管理办法》等法律、法规及《北 京阳光诺和药物研究股份有限公司章程》的有关规定。 经与会独立董事审议，同意公司拟通过发行股份及可转换公司债券方式购买 江苏朗研生命科技控股有限公司 100%股权，并向不超过 35 名特定投资者发行股 份募集配套资金（以下简称"本次交易"）相关议案并同意提交公司第二届董事 会第十九次会议审议，现发表审核意见如下： 市公司重大资产重组管理办法》《上海证券交易所上市公司重大资产重组审核规 则》 《上市公司证券发行注册管理办法》 《上市公司向特定对象发行可转换公司债 券购买资产规则》等法律、法规和规范性文件关于发行股份及可转换公司债券购 买资产并募集配套资金的规定。 议通过，关联董事回避表决。本次董事会的召集和召开程序、表决程序及方式符 合相关法律、法规及公司章程的规定。根据《上 ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 京天股字（2025）第 224 号 致：北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称公司）2025 年第一次临时股 东会（以下简称本次股东会）采取现场投票与网络投票相结合的方式，现场会议于 议室召开。北京市天元律师事务所（以下简称本所）接受公司聘任，指派本所律师 现场参加本次股东会现场会议并对本次股东会现场进行见证，并根据《中华人民共 和国公司法》《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东 会规则》（以下简称《股东会规则》）以及《北京阳光诺和药物研究股份有限公司 章程》（以下简称《公司章程》）等有关规定，就本次股东会的召集、召开程序、 出席现场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法 律意见。 为出具本法律意见，本所律师审查了《北京阳光诺和药物研究股份有限公司第 二届董事会第十八次会议决议公告》《北京阳光诺和药物研究股份有限公司关于召 开 2025 年第一次临时股东会的通知》（以下简称《召开股东会通知》）以及本所 律师认为必要的其他文件和资料，同时审查了出席现场会议股东的身份和 ...

Company Overview - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. specializes in comprehensive preclinical and clinical drug research services, providing a one-stop drug development service for domestic pharmaceutical companies and research institutions [2] - The company aims to assist domestic pharmaceutical manufacturers in accelerating import substitution and independent innovation [2] - Major products include drug discovery, pharmacology, pharmaceutical research, clinical research, and bioanalysis [2] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.078 billion yuan, representing a year-on-year increase of 15.70% [2] - The net profit for the same period was 177 million yuan, showing a year-on-year decrease of 3.98% [2] - The sales gross margin stood at 50.18% [2] Market Position - As of April 18, the company's stock closed at 45.24 yuan, with a PE ratio of 28.56, marking an 11-day low [1] - The total market capitalization is 5.067 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 45.89, with a median of 48.60, placing Sunshine Nuohe at the 21st position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for Sunshine Nuohe reached 8,025, an increase of 455 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 根据中国证券监督管理委员会出具的《关于同意北京阳光诺和药物研究股份有限公司首次公开发行股票 注册的批复》（证监许可【2021】1629号），同意北京阳光诺和药物研究股份有限公司（以下简称"阳 光诺和"、"公司"）首次公开发行股票的注册申请，公司获准向社会公开发行人民币普通股20,000,000 股。每股面值为1元，每股发行价格为26.89元，募集资金总额537,800,000.00元。上述募集资金总额扣除 发行费用70,618,507.55元（相关费用均为不含税金额）后，本次公司公开发行新股的募集资金净额 467,181,492.45元。本次发行证券已于2021年6月21日在上海证券交易所科创板上市。民生证券股份有限 公司（以下简称"保荐机构"或"民生证券"）担任其持续督导保荐机构，持续督导期间为2021年6月21日 至2024年12月31日。 2024年12月31日，持续督导期已届满，民生证券根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号一一规范运作》等法 规、规范性文件相关要求，出 ...